Today's Highlights
Premium
Rocket Pharmaceuticals Announced FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I
Rocket Pharmaceuticals in the NEWS March 27, 2026, Rocket Pharmaceuticals ( RCKT ) announced that the U.S. FDA has granted accelerated approval for KRESLADI™ (marnetegragene autotemcel), an autologous...
P
Prohost Biotech
1 min read
60
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Comments (0)
Please sign in to join the discussion